A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. Recursion Pharmaceuticals Inc’s current trading price is -52.75% away from its 52-week high, while its distance from the 52-week low is 54.09%. The stock’s price range for this time frame has been between $3.79 and $12.36. The trading volume of the company’s shares in the Healthcare reached around 52.75 million for the day, which was evidently higher than the average daily volume of 25.55 million over the last three months.
Recursion Pharmaceuticals Inc (RXRX) has a current stock price of $5.84. During the previous trading session, the stock witnessed a notable rise, reaching a high of $10.0 after opening at $5.84. The stock’s low for the day was $4.0, and it eventually closed at $5.52.
The market performance of Recursion Pharmaceuticals Inc has been somewhat unstable. Over the past year, the company’s stock achieved a high of $12.36 on 02/18/25, with the lowest value for the same timeframe being $3.79, recorded on 04/09/25.
How Financial Performance Impacts Market Capitalization
Recursion Pharmaceuticals Inc (RXRX) has experienced a quarterly rise of 9.77% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.52B.
Decoding Analysts’ Ratings for Recursion Pharmaceuticals Inc
As of right now, 1 analyst is rating Recursion Pharmaceuticals Inc as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 6 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 5.39, with a change in price of -3.16. Similarly, Recursion Pharmaceuticals Inc recorded 24,625,895 in trading volume during the last 100 days, posting a change of -35.11%.
How RXRX’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for RXRX stands at 0.10. Similarly, the long-term debt-to-equity ratio is also 0.08.
RXRX Stock Stochastic Average
The raw stochastic average for Recursion Pharmaceuticals Inc over the last 50 days is presently at 83.00%. This reflects a surge from the raw stochastic average of the previous 20 days, which was noted at 74.42%. Further, the company’s Stochastic %K and %D values for the last 20 days were 67.07% and 57.82%, respectively.
RXRX Stock Price Performance Analysis
The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. The index has shown a price loss of -32.09% this year. Over the last six months, there has been a stronger performance of -9.03%. The price of RXRX fallen by 20.66% during the last 30 days period. For the last 5-days stocks have improved 10.61%.
